TruScreen Group Limited
TRU.NZ
New Zealand Exchange0.02
NZD
+0.00
- -
TruScreen Group Limited
TRU.NZ
(New Zealand Exchange)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- TruScreen Group Limited is a New Zealand and Australian listed medical device company specializing in the development and commercialization of AI-enabled cervical cancer screening technology. The company manufactures and distributes the TruScreen Cervical Cancer Screening Device, which utilizes proprietary optoelectrical technology combining optical and electrical measurements to detect pre-cancerous and cancerous cervical tissue in real time. TruScreen's product offerings focus on cervical cancer screening solutions designed for use in hospitals, clinics, and public health programs, targeting early detection of cervical intraepithelial neoplasia (CIN) to support cancer prevention. Founded in 2013 and headquartered in Auckland, New Zealand, TruScreen operates across multiple global markets including New Zealand, Australia, China, Vietnam, Mexico, Russia, Indonesia, Uzbekistan, Zimbabwe, and other regions. The company’s products predominantly serve public and private healthcare sectors in these countries, aiming to enhance screening accessibility, especially in low- and middle-income countries with large female populations of screening age. Recent major company developments include a strategic non-binding Memorandum of Understanding (MOU) signed in February 2025 with Hangzhou Dalton Bioscience, a leading Chinese manufacturer of HPV DNA tests and laboratory equipment. Under this alliance, TruScreen will become the global distributor of DaltonBio's HPV-related in vitro diagnostic (IVD) products (excluding the US and Canada), expanding its cervical cancer screening portfolio and distribution reach in China and South America. In addition, TruScreen has launched a 5-year cervical cancer screening program targeting 260,000 women in Ho Chi Minh City, Vietnam, which commenced in April 2025. The company has also appointed a new distributor for Indonesia, with commercial sales expected to begin shortly, and secured regulatory approval to enter the Uzbekistan market. Furthermore, TruScreen completed a $2.3 million capital raise in mid-2025 to support growth initiatives and expand global market penetration. These strategic moves complement TruScreen’s ongoing expansion in public health insurance reimbursement approvals in China, with pricing established in 11 provinces and ongoing efforts in Beijing and Shanghai. The company focuses on leveraging AI technology to deliver rapid, accurate screening solutions, aiming to improve early cervical cancer detection globally, thereby addressing significant public health challenges in both developed and developing healthcare environments. TruScreen Group Limited continues to invest in regulatory approvals, market expansion, and partnerships to drive growth and enhance its comprehensive cervical screening platform internationally.